https://distefar.com/en/clinical-trials-area-of-the-hospital-pharmacy-service/2026-03-16T00:22:43+01:00https://distefar.com/en/astrazeneca-foundation-encourages-young-talent-with-80000-euros/2026-03-16T00:22:43+01:00https://distefar.com/en/lilly-foundation-awards-a-study-of-protein-kinase-in-liver-disease/2026-03-16T00:22:44+01:00https://distefar.com/en/isciii-will-represent-spain-in-the-largest-research-appointment-in-europe/2026-03-16T00:22:44+01:00https://distefar.com/en/ema-gives-a-positive-opinion-to-gilenya-from-novartis-for-minors-with-multiple-sclerosis/2026-03-16T00:22:44+01:00https://distefar.com/en/nobel-prize-for-medicine-2018-for-cancer-immunotherapy/2026-03-16T00:22:44+01:00https://distefar.com/en/vhio-develops-a-precision-immunotherapy-for-breast-cancer/2026-03-16T00:22:44+01:00https://distefar.com/en/genetic-mutations-also-alter-the-nature-of-clinical-trials/2026-03-16T00:22:44+01:00https://distefar.com/en/europe-approves-verzenios-from-lilly-for-the-treatment-of-advanced-breast-cancer/2026-03-16T00:22:44+01:00https://distefar.com/en/clinical-trials-area-of-the-hospital-pharmacy-service-2/2018-03-14T11:39:04+01:00https://distefar.com/en/astrazeneca-foundation-encourages-young-talent-with-80000-euros-2/2018-09-13T13:49:22+02:00https://distefar.com/en/lilly-foundation-awards-a-study-of-protein-kinase-in-liver-disease-2/2018-09-18T12:09:19+02:00https://distefar.com/en/isciii-will-represent-spain-in-the-largest-research-appointment-in-europe-2/2018-09-21T11:21:48+02:00https://distefar.com/en/ema-gives-a-positive-opinion-to-gilenya-from-novartis-for-minors-with-multiple-sclerosis-2/2018-09-26T12:02:23+02:00https://distefar.com/en/nobel-prize-for-medicine-2018-for-cancer-immunotherapy-2/2018-10-03T15:47:05+02:00https://distefar.com/en/vhio-develops-a-precision-immunotherapy-for-breast-cancer-2/2018-10-05T11:23:17+02:00https://distefar.com/en/genetic-mutations-also-alter-the-nature-of-clinical-trials-2/2018-10-08T11:00:31+02:00https://distefar.com/en/europe-approves-verzenios-from-lilly-for-the-treatment-of-advanced-breast-cancer-2/2018-10-10T12:35:53+02:00https://distefar.com/en/success-of-the-first-trial-of-opsumit-actelion-in-portopulmonary-hypertension/2018-10-16T11:57:18+02:00https://distefar.com/en/breast-cancer-the-industry-leads-the-research-of-169-new-drugs/2018-10-18T16:46:59+02:00https://distefar.com/en/gilead-increases-its-commitment-to-research-in-spain-targeting-hiv/2018-10-19T13:54:29+02:00https://distefar.com/en/new-advances-in-the-treatment-of-head-and-neck-tumors/2018-10-23T11:07:35+02:00https://distefar.com/en/cataluna-allocates-9-5-million-to-peris-its-health-innovation-plan/2018-10-25T11:35:56+02:00https://distefar.com/en/the-aemps-publishes-new-features-in-the-treatment-of-drug-registration-dossiers/2018-10-30T12:12:49+01:00https://distefar.com/en/enhance-r-d-and-protect-intellectual-property-petitions-from-the-pharmaceutical-industry-to-europe/2018-11-05T12:39:19+01:00https://distefar.com/en/europe-approves-a-new-indication-for-xtandi-from-astellas-for-prostate-cancer/2018-11-08T11:03:37+01:00https://distefar.com/en/ema-publishes-a-report-on-the-impact-of-brexit-on-the-authorization-of-medicines/2018-11-15T10:16:37+01:00https://distefar.com/en/astra-zeneca-presents-new-indications-on-the-benefits-of-brilique/2018-11-16T10:23:27+01:00https://distefar.com/en/novartis-works-with-50-molecules-in-the-development-of-new-cart-therapies/2018-11-20T12:38:34+01:00https://distefar.com/en/incliva-shows-the-possible-improvement-of-atherosclerosis-through-a-molecule/2018-11-22T15:25:18+01:00https://distefar.com/en/farma-biotech-promotes-nine-projects-on-innovative-drugs/2018-11-29T16:03:12+01:00https://distefar.com/en/more-than-130000-patients-participate-in-3000-clinical-trials-in-spain/2018-12-04T12:58:07+01:00https://distefar.com/en/advances-in-therapies-directed-to-lymphocytes-in-systemic-lupus-erythematosus/2018-12-12T15:06:21+01:00https://distefar.com/en/combining-metformin-and-an-antihypertensive-is-effective-against-tumors/2018-12-14T13:53:46+01:00https://distefar.com/en/new-method-for-the-prediction-of-response-to-treatment-in-clinical-trials/2018-12-20T12:43:17+01:00https://distefar.com/en/investigations-of-the-carlos-iii-national-center-for-cardiovascular-research/2018-12-26T11:30:28+01:00https://distefar.com/en/a-new-refinement-increases-the-safety-of-car-t-therapy/2019-01-08T11:46:52+01:00https://distefar.com/en/aemps-corrects-its-document-on-instructions-for-clinical-trials-in-spain/2019-01-14T10:37:27+01:00https://distefar.com/en/the-carlos-iii-health-institute-announces-new-european-calls-for-research/2019-01-22T11:47:42+01:00https://distefar.com/en/develop-new-medicines-make-them-accessible-in-a-sustainable-environment-and-attract-investments-to-the-country-objectives-of-the-pharmaceutical-industry-in-spain/2019-02-12T10:54:35+01:00https://distefar.com/en/spain-attracts-more-than-250-clinical-trials-in-oncohematology-in-the-last-four-years/2019-02-13T12:16:14+01:00https://distefar.com/en/one-of-every-six-clinical-trials-that-is-carried-out-in-spain-is-already-to-investigate-orphan-drugs/2019-02-19T12:32:20+01:00https://distefar.com/en/the-effective-participation-of-patients-essential-for-the-success-of-clinical-trials/2019-02-22T12:20:34+01:00https://distefar.com/en/javier-urzay-deputy-director-of-farmaindustria-we-want-to-turn-spain-into-one-of-the-most-attractive-places-in-the-world-to-do-biomedical-research/2019-02-25T13:23:27+01:00https://distefar.com/en/first-criteria-to-offer-t-car-therapies-health-figure-between-5-and-7-reference-hospitals/2019-02-27T10:28:50+01:00https://distefar.com/en/the-aemps-explains-how-to-apply-for-the-temporary-exemption-for-batch-control-in-the-united-kingdom/2019-03-07T10:13:25+01:00https://distefar.com/en/the-pharmaceutical-industry-has-doubled-its-investment-in-clinical-research-in-spain-since-2005/2019-03-12T13:44:55+01:00https://distefar.com/en/promote-r-d-ensure-access-and-measure-results-keys-to-the-future-in-oncological-drugs/2019-03-13T10:00:57+01:00https://distefar.com/en/the-association-of-pharmaceutical-industry-discusses-counterfeit-medicines/2019-03-15T12:17:51+01:00https://distefar.com/en/roche-launches-a-clinical-trials-platform-focused-on-the-needs-of-patients/2019-03-19T10:52:13+01:00https://distefar.com/en/spain-before-a-historic-opportunity-in-the-commitment-to-clinical-trials/2019-04-09T12:04:06+02:00https://distefar.com/en/clinical-trials-provide-a-positive-economic-impact-on-the-nhs/2019-04-11T12:22:33+02:00https://distefar.com/en/new-agenda-of-the-aemps-management-by-objectives-and-supply-plan/2019-04-12T10:10:08+02:00https://distefar.com/en/the-protection-of-intellectual-property-key-to-the-development-of-new-medicines/2019-04-29T10:23:15+02:00https://distefar.com/en/an-atlas-at-the-individual-cell-level-will-improve-precision-medicine-in-breast-cancer/2019-05-02T12:33:00+02:00https://distefar.com/en/conference-university-research-and-regulatory-compliance-of-the-rgpd/2019-05-24T14:20:03+02:00https://distefar.com/en/ahorro-de-10-000-euros-paciente-por-los-ensayos-clinicos-de-la-industria-2/2019-05-24T14:21:38+02:00https://distefar.com/en/clinical-trials-key-to-developing-new-drugs-and-valuable-for-the-economy-and-cost-savings-health/2019-05-24T14:24:32+02:00https://distefar.com/en/the-resignation-of-may-dilates-the-concern-of-the-pharmaceutical-companies-before-a-brexit-without-agreement/2019-05-27T12:14:10+02:00https://distefar.com/en/car-t-therapy-future-option-to-improve-the-treatment-of-multiple-myeloma/2019-05-30T10:22:18+02:00https://distefar.com/en/spain-takes-a-step-forward-in-clinical-research-in-early-phases-in-pediatrics-and-rare-diseases/2019-06-11T13:10:32+02:00https://distefar.com/en/private-healthcare-already-participates-in-half-of-clinical-trials/2019-06-17T11:05:08+02:00https://distefar.com/en/the-pharmaceutical-industry-facilitates-the-participation-of-more-than-150000-patients-in-clinical-trials-in-the-last-12-years/2019-06-24T13:26:53+02:00https://distefar.com/en/pharmaceutical-companies-managers-healthcare-professionals-and-researchers-seek-to-strengthen-the-excellence-of-clinical-trials-in-spain/2019-07-16T11:59:45+02:00https://distefar.com/en/spanish-society-should-know-that-participating-in-a-clinical-trial-is-something-beneficial/2019-07-18T10:41:34+02:00https://distefar.com/en/each-year-15000-patients-participate-in-clinical-trials-promoted-by-the-pharmaceutical-industry-in-spain/2019-07-22T11:30:49+02:00https://distefar.com/en/a-global-and-long-term-analysis-of-the-medication-is-essential-to-consider-all-its-health-economic-and-social-benefits/2019-07-29T14:32:47+02:00https://distefar.com/en/pharmaceutical-companies-reaffirm-their-commitment-to-research-and-access-to-innovation-in-spain/2019-09-10T08:45:35+02:00https://distefar.com/en/the-pharmaceutical-industry-develops-in-spain-almost-200-clinical-trials-on-lung-cancer/2019-09-16T15:30:56+02:00https://distefar.com/en/new-drugs-in-cardiovascular-disease-a-success-story/2019-09-30T16:05:23+02:00https://distefar.com/en/more-hospitals-aspire-to-become-car-t-centers/2019-10-03T10:21:34+02:00https://distefar.com/en/the-pharmaceutical-industry-strengthens-its-commitment-to-pediatric-clinical-research-and-already-promotes-nine-out-of-ten-trials-in-this-field/2026-03-16T11:53:46+01:00https://distefar.com/en/the-pharmaceutical-industry-has-in-the-rd-phase-140-new-medicines-against-mental-disorders/2026-03-16T11:53:52+01:00https://distefar.com/en/investment-in-rd-of-the-pharmaceutical-industry-a-value-for-the-whole-society/2019-11-05T12:54:36+01:00https://distefar.com/en/the-pharmaceutical-industry-already-invests-more-than-660-million-euros-a-year-in-clinical-research-in-spain/2019-11-07T17:10:21+01:00https://distefar.com/en/the-pharmaceutical-industry-reaffirms-its-commitment-to-rd-in-rare-diseases/2019-11-11T10:21:25+01:00https://distefar.com/en/wewontrest-until-we-beat-alzheimers-disease-together/2019-11-15T11:53:37+01:00https://distefar.com/en/farmaindustria-reinforces-the-collaboration-to-promote-clinical-research-in-spain/2019-11-20T10:16:12+01:00https://distefar.com/en/andalusian-high-school-students-are-interested-in-drug-rd/2019-11-27T11:04:03+01:00https://distefar.com/en/we-have-put-the-name-of-vall-dhebron-on-the-map-of-world-oncology/2019-12-11T11:03:49+01:00https://distefar.com/en/the-pharmaceutical-industry-accelerates-against-lung-cancer-the-one-with-the-highest-mortality-in-spain/2020-01-08T13:49:18+01:00https://distefar.com/en/the-keys-that-can-turn-spain-into-a-reference-for-biomedical-research/2020-01-10T11:01:30+01:00https://distefar.com/en/2019-a-new-year-of-progress-and-remarkable-progress-for-pharmaceutical-innovation/2020-01-13T15:19:24+01:00https://distefar.com/en/the-economic-and-social-council-advises-the-government-to-promote-investment-in-rd/2020-01-16T12:33:54+01:00https://distefar.com/en/clinical-trials-cost-savings-for-the-system-and-innovative-therapies-for-the-patient/2020-01-28T11:33:06+01:00https://distefar.com/en/the-pharmaceutical-industry-responds-to-the-increased-incidence-of-cancer-one-in-two-clinical-trials-focuses-on-oncology/2020-02-05T11:42:26+01:00https://distefar.com/en/clinical-research-in-spain-seeks-new-impulses-to-maintain-its-leadership-position-in-europe/2020-02-06T10:27:56+01:00https://distefar.com/en/sefh-joins-the-world-cancer-day-recalling-the-importance-of-healthy-habits-and-research/2020-02-07T13:34:31+01:00https://distefar.com/en/drug-rd-increasingly-high-development-costs-and-lower-returns/2020-02-10T13:09:07+01:00https://distefar.com/en/create-the-test-that-predicts-the-risk-of-infection-in-kidney-transplants/2020-02-24T11:30:35+01:00https://distefar.com/en/the-pharmaceutical-sector-the-basis-of-a-new-production-model-in-spain/2020-03-04T15:17:57+01:00https://distefar.com/en/the-pharmaceutical-industry-warns-of-the-risk-of-europe-becoming-a-non-driving-receiving-market-for-innovation/2020-03-09T12:38:55+01:00https://distefar.com/en/exceptional-measures-for-tests-for-problems-derived-from-the-emergency-by-covid-19/2020-03-18T10:57:51+01:00https://distefar.com/en/spain-a-world-leader-in-conducting-clinical-trials-of-new-drugs/2020-04-20T10:36:22+02:00https://distefar.com/en/new-clinical-trial-designs-and-more-resources-for-spain-to-achieve-excellence/2020-04-21T11:26:15+02:00https://distefar.com/en/objective-to-maintain-clinical-trials-without-putting-patients-health-at-risk/2020-04-27T13:44:04+02:00https://distefar.com/en/drug-research-as-an-opportunity-for-spain/2020-05-12T10:26:35+02:00https://distefar.com/en/world-asthma-day-fifty-hundred-medicines-in-development-for-one-of-the-most-prevalent-pathologies/2020-05-14T11:53:14+02:00https://distefar.com/en/almost-a-thousand-clinical-trials-more-than-230-drugs-and-vaccines-to-combat-covid-19/2020-05-22T12:06:08+02:00https://distefar.com/en/novo-nordisk-spain-increases-patients-in-clinical-trials-by-50-in-three-years/2020-05-25T11:23:59+02:00https://distefar.com/en/the-clinical-trial-a-value-bet-for-the-healthcare-system-professionals-patients-and-industry/2020-05-26T11:17:54+02:00https://distefar.com/en/collaboration-between-the-healthcare-system-and-the-pharmaceutical-industry-key-for-spain-to-consolidate-its-leadership-in-clinical-trials/2020-06-08T13:55:44+02:00https://distefar.com/en/spain-a-pioneer-country-against-counterfeiting-drugs/2020-06-16T11:27:32+02:00https://distefar.com/en/quality-employment-more-investment-in-research-and-more-production-in-spain-pharmaceutical-industry-proposals-for-economic-and-social-reconstruction/2020-06-18T10:31:04+02:00https://distefar.com/en/the-rerfar-covid19-sefh-registry-identifies-drugs-that-reduce-mortality-from-the-disease/2020-06-23T10:48:06+02:00https://distefar.com/en/investment-in-research-and-recovery-of-production-bases-to-revive-the-economy/2020-06-25T10:56:34+02:00https://distefar.com/en/approved-the-call-for-independent-clinical-trials-of-the-carlos-iii-health-institute/2020-07-08T11:49:56+02:00https://distefar.com/en/the-coronavirus-crisis-shows-the-importance-of-promoting-the-digital-transformation-of-healthcare/2020-07-14T10:58:15+02:00https://distefar.com/en/clinical-trials-recover-normality-after-the-sanitary-crisis/2020-07-21T09:47:15+02:00https://distefar.com/en/spain-protagonist-in-clinical-trials-to-find-the-coronavirus-vaccine/2020-09-03T10:47:20+02:00https://distefar.com/en/they-identify-a-key-protein-to-prevent-breast-cancer-metastasis/2020-09-10T14:40:33+02:00https://distefar.com/en/aemps-recommendations-on-covid19-to-the-pharmaceutical-industry-and-distribution/2020-09-11T12:24:29+02:00https://distefar.com/en/arranca-el-primer-ensayo-en-humanos-de-una-vacuna-covid-19-en-espana-2/2020-09-15T10:34:41+02:00https://distefar.com/en/comprehensive-commitment-of-the-pharmaceutical-industry-to-patient-safety/2020-09-17T10:13:18+02:00https://distefar.com/en/the-fight-against-cancer-is-not-stopped-by-the-coronavirus-four-out-of-ten-new-investigational-drugs-are-antitumor/2020-09-28T12:21:09+02:00https://distefar.com/en/immunotherapy-before-surgery-doubles-survival-in-lung-cancer/2020-10-02T11:52:30+02:00https://distefar.com/en/covid-19-has-delayed-cancer-clinical-trial-programs/2020-10-05T10:05:37+02:00https://distefar.com/en/research-in-breast-cancer-more-survival-and-better-quality-of-life/2020-10-20T11:00:29+02:00https://distefar.com/en/bms-celebrates-the-first-international-forum-aimed-at-the-research-community-of-spain-and-portugal/2020-10-21T13:26:53+02:00https://distefar.com/en/farmaindustria-bets-on-digitization-to-consolidate-spain-in-drug-trials/2026-03-16T12:04:46+01:00https://distefar.com/en/takeda-launches-a-website-that-groups-all-its-clinical-trials/2026-03-16T12:04:51+01:00https://distefar.com/en/regulatory-alignment-and-mutual-recognition-for-the-manufacture-of-medicines-needs-of-the-pharmaceutical-industry-in-the-face-of-brexit/2020-11-09T14:10:27+01:00https://distefar.com/en/eight-drug-projects-of-small-spanish-companies-attract-the-interest-of-pharmaceutical-companies/2020-11-19T13:00:02+01:00https://distefar.com/en/the-royal-decree-that-regulates-observational-studies-with-medicines-for-human-use-approved/2020-11-30T10:03:20+01:00https://distefar.com/en/the-pharmaceutical-industry-once-again-sets-a-record-for-investment-in-rd-in-spain/2020-12-09T14:40:04+01:00https://distefar.com/en/why-might-the-development-of-a-new-drug-take-more-than-10-years/2020-12-14T12:54:52+01:00https://distefar.com/en/carts-effective-for-solid-tumors-not-just-blood-cancers/2021-01-26T14:34:29+01:00https://distefar.com/en/cancer-the-fight-is-not-stopped-by-the-covid-4-out-of-10-investigational-drugs-are-antitumor/2021-02-05T10:37:17+01:00https://distefar.com/en/clinical-trials-this-is-how-drugs-and-vaccines-are-designed/2021-02-23T10:41:20+01:00https://distefar.com/en/20-of-clinical-trials-in-spain-are-already-focused-on-rare-diseases/2021-03-04T12:38:30+01:00https://distefar.com/en/promoting-the-use-of-biomarkers-improves-cancer-diagnosis-and-treatment/2021-03-11T11:57:39+01:00https://distefar.com/en/spain-launched-44-clinical-trials-for-cardiovascular-diseases-in-2020/2021-03-17T14:06:00+01:00https://distefar.com/en/observational-studies-with-drugs-published-in-the-spanish-trial-registry/2021-04-15T10:56:24+02:00https://distefar.com/en/digitization-in-clinical-research-advances-for-the-benefit-of-patients/2021-04-27T12:51:58+02:00https://distefar.com/en/europe-has-the-challenge-of-regaining-ground-lost-to-the-us-and-asia-in-drug-research/2021-05-06T13:18:53+02:00https://distefar.com/en/the-pharmaceutical-industry-has-almost-90-drugs-under-development-against-antimicrobial-resistance/2021-05-10T11:56:34+02:00https://distefar.com/en/spain-a-country-of-reference-in-conducting-clinical-trials/2021-05-20T11:15:09+02:00https://distefar.com/en/the-investment-of-the-pharmaceutical-industry-in-rd-grows-in-2020-despite-the-pandemic/2021-05-21T13:39:32+02:00https://distefar.com/en/the-medicine-health-social-and-economic-value/2021-06-08T08:36:25+02:00https://distefar.com/en/farmaindustria-estimates-the-investment-in-2020-of-pharmaceutical-companies-in-research-at-39000-million/2021-06-21T10:41:38+02:00https://distefar.com/en/the-md-anderson-cancer-center-in-madrid-inaugurates-one-of-the-largest-phase-i-clinical-trials-units-in-europe/2021-11-04T13:40:07+01:00https://distefar.com/en/the-aemps-publishes-the-memorandum-of-ethics-committees-for-drug-research/2021-11-17T10:27:36+01:00https://distefar.com/en/the-pandemic-has-shown-that-more-autonomous-communities-can-host-clinical-trials-of-drugs-which-is-hopeful-for-many-patients/2021-12-13T13:07:22+01:00https://distefar.com/en/seven-out-of-ten-drugs-in-clinical-development-are-first-in-class/2022-01-24T11:53:15+01:00https://distefar.com/en/spain-can-benefit-from-the-new-european-harmonization-of-clinical-trials/2022-02-03T11:04:19+01:00https://distefar.com/en/the-new-european-harmonization-of-clinical-trials-an-opportunity-to-attract-more-investment-to-spain/2022-02-09T08:36:39+01:00https://distefar.com/en/cnio-scientific-leadership-in-oncology-research/2022-02-14T12:21:38+01:00https://distefar.com/en/high-intratumoural-heterogeneity-of-endometrial-cancer-revealed/2022-02-18T08:27:36+01:00https://distefar.com/en/hospital-puerta-de-hierro-joins-a-clinical-trial-that-could-change-the-paradigm-of-lung-cancer/2022-03-22T09:31:10+01:00https://distefar.com/en/our-code-of-conduct-on-data-protection-in-clinical-trials-and-pharmacovigilance-is-a-benchmark-for-the-future-european-code/2022-04-21T09:39:01+02:00https://distefar.com/en/clinical-trial-succeeds-in-eliminating-cancer-in-all-participants/2022-06-09T11:11:52+02:00https://distefar.com/en/the-digital-transformation-of-biomedical-research-must-be-deployed-with-full-safeguards-for-patients/2026-03-16T12:18:55+01:00https://distefar.com/en/how-research-into-new-medicines-changes-peoples-lives/2022-06-13T11:50:30+02:00https://distefar.com/en/farmaindustria-highlights-the-consolidation-of-spains-leadership-in-biomedical-rd-within-the-strategic-plan-of-the-pharmaceutical-industry/2022-06-24T13:00:12+02:00https://distefar.com/en/more-training-and-information-to-move-towards-excellence-in-clinical-trials-in-spain/2022-07-19T10:41:08+02:00https://distefar.com/en/argentinean-health-authorities-and-pharmaceutical-industry-are-interested-in-the-keys-to-spains-leadership-in-clinical-research/2022-09-27T11:24:46+02:00https://distefar.com/en/biomedical-rd-advances-in-the-aftermath-of-the-pandemic-the-pharmaceutical-industry-has-8000-drugs-under-investigation-10-of-them-for-rare-diseases/2022-10-17T10:57:07+02:00https://distefar.com/en/the-pharmaceutical-industry-leads-the-world-in-rd-investment-it-now-exceeds-200-billion-a-year/2022-10-25T14:10:56+02:00https://distefar.com/en/multiple-sclerosis-patients-interested-in-clinical-trials/2022-10-27T09:44:25+02:00https://distefar.com/en/there-must-be-a-national-commitment-for-spain-to-remain-at-the-forefront-of-clinical-research/2022-11-10T09:16:16+01:00https://distefar.com/en/europe-is-losing-weight-in-rd-investment-in-new-drugs-in-the-face-of-us-and-chinas-drive/2022-11-15T10:12:54+01:00https://distefar.com/en/new-drugs-associated-with-a-29-reduction-in-cancer-deaths-in-spain-in-a-single-year/2022-11-21T13:59:16+01:00https://distefar.com/en/aemps-bulletin-november-2022-on-medicinal-products-for-human-use/2022-12-01T12:11:48+01:00https://distefar.com/en/farmaindustria-promotes-the-creation-of-a-working-group-to-promote-clinical-trials-in-primary-care/2022-12-12T11:15:59+01:00https://distefar.com/en/revolutionary-therapy-targets-the-most-serious-cancers-by-doping-the-immune-system/2022-12-13T10:32:41+01:00https://distefar.com/en/the-pharmaceutical-industry-reinforces-its-commitment-to-spain-and-sets-a-new-record-in-rd-investment-with-1267-million-euros/2022-12-20T10:10:30+01:00https://distefar.com/en/spain-is-one-of-the-european-countries-with-the-greatest-potential-for-the-manufacture-of-medicines/2023-01-10T09:36:10+01:00https://distefar.com/en/spain-registers-more-than-900-clinical-trials-in-2022-above-pre-pandemic-levels/2023-01-17T09:44:41+01:00https://distefar.com/en/pharmaceutical-industry-launches-project-to-promote-patient-participation-in-cross-border-clinical-trials-in-the-eu/2023-01-23T14:49:19+01:00https://distefar.com/en/the-pharmaceutical-industry-reaches-a-record-figure-for-research-and-development-of-new-medicines/2023-01-30T12:29:15+01:00https://distefar.com/en/hm-hospitales-puts-the-number-of-patients-in-clinical-trials-of-its-research-foundation-in-2022-at-almost-1300/2023-02-06T10:16:49+01:00https://distefar.com/en/it-is-necessary-to-establish-a-system-of-early-access-to-drugs-that-provide-greater-clinical-benefit-to-cancer-patients/2023-02-13T15:04:57+01:00https://distefar.com/en/promoting-rd-equity-access-and-measurement-of-health-outcomes-priorities-for-the-pharmaceutical-industry-in-the-fight-against-cancer/2023-02-21T09:42:48+01:00https://distefar.com/en/paediatric-clinical-trials-to-grow-by-24-by-2022-with-special-focus-on-cancer-and-nervous-system-diseases/2023-03-08T09:50:05+01:00https://distefar.com/en/spain-authorised-more-than-900-clinical-trials-with-medicines-in-2022-according-to-the-spanish-clinical-trials-register-reec-these-figures-exceed-those-recorded-in-the-years-prior-to-the-pandemic/2023-03-13T12:25:05+01:00https://distefar.com/en/fifteen-organisations-sign-up-to-the-code-on-data-protection-in-clinical-trials-in-its-first-year/2023-04-17T10:22:17+02:00https://distefar.com/en/its-time-for-europe-to-make-up-for-lost-ground-in-pharmaceutical-innovation/2023-04-24T13:54:32+02:00https://distefar.com/en/farmaindustria-assures-that-the-revision-of-the-european-pharmaceutical-legislation-puts-the-future-of-the-industry-at-risk/2023-05-02T14:22:51+02:00https://distefar.com/en/bringing-clinical-trials-closer-to-the-patients-home-is-a-challenge-in-which-the-public-and-private-sectors-must-go-hand-in-hand/2023-05-08T12:30:12+02:00https://distefar.com/en/the-increase-in-international-competitiveness-and-digitalisation-will-require-more-investment-to-ensure-that-spain-remains-at-the-forefront-of-biomedical-rd/2023-05-11T09:39:29+02:00https://distefar.com/en/clinical-trials-hope-for-todays-patients-and-new-medicines-for-tomorrows-patients/2023-05-22T14:14:46+02:00https://distefar.com/en/the-availability-of-oncology-drugs-needs-to-improve-as-only-57-of-those-approved-in-europe-are-available/2023-05-25T10:03:38+02:00https://distefar.com/en/xvi-annual-conference-of-biomedical-research-technology-platforms/2023-05-30T11:57:58+02:00https://distefar.com/en/difficulties-in-access-to-orphan-drugs-in-spain-are-detrimental-to-patients-the-healthcare-system-and-pharmaceutical-companies/2023-06-05T13:18:31+02:00https://distefar.com/en/we-must-bring-clinical-trials-closer-to-the-patients-home-and-for-this-research-in-primary-care-is-vital/2023-06-19T13:47:27+02:00https://distefar.com/en/spain-a-global-power-in-clinical-trials/2023-06-27T09:26:09+02:00https://distefar.com/en/pharmaceutical-companies-set-a-record-for-investment-in-collaborations-with-the-healthcare-system-through-rd-and-support-for-lifelong-learning/2023-07-04T09:18:30+02:00https://distefar.com/en/the-pharmaceutical-industry-one-of-the-most-value-added-sectors-in-europe/2023-07-10T14:59:20+02:00https://distefar.com/en/the-22nd-meeting-of-the-spanish-pharmaceutical-industry-will-focus-on-the-reform-of-european-legislation-and-its-impact-on-spain/2023-07-18T10:43:21+02:00https://distefar.com/en/the-rise-of-combination-therapies-in-cancer-opens-up-an-opportunity-for-patients-but-requires-improved-access-procedures/2023-07-25T08:59:43+02:00https://distefar.com/en/improving-patient-access-to-innovative-medicines-and-boosting-rd-and-manufacturing-in-spain-are-the-main-priorities-of-the-pharmaceutical-industry/2023-09-12T10:52:54+02:00https://distefar.com/en/health-commitment-to-the-pharmaceutical-industrys-strategic-plan-to-avoid-losing-8000-million-euros/2023-09-14T13:21:19+02:00https://distefar.com/en/the-pharmaceutical-industrys-plan-to-expand-clinical-trials-in-primary-care/2023-09-19T10:18:09+02:00https://distefar.com/en/mas-de-120-moleculas-en-investigacion-para-el-alzheimer-la-gran-esperanza-para-pacientes-familiares-y-sociedad-2/2023-09-26T13:46:04+02:00https://distefar.com/en/descentralizacion-de-ensayos-trabajo-en-red-y-digitalizacion-propuestas-para-mejorar-la-participacion-de-los-pacientes-en-la-investigacion-clinica-2/2023-10-02T13:54:56+02:00https://distefar.com/en/la-inteligencia-artificial-y-la-tecnologia-estan-impulsando-las-terapias-digitales-que-benefician-no-solo-a-los-pacientes-sino-al-sistema-sanitario-y-al-conjunto-de-la-sociedad-2/2023-10-04T08:29:03+02:00https://distefar.com/en/la-investigacion-clinica-pediatrica-avanza-en-espana-impulsada-por-la-colaboracion-entre-investigadores-profesionales-sanitarios-y-la-industria-farmaceutica-2/2023-10-09T13:51:34+02:00https://distefar.com/en/urgent-measures-are-needed-to-encourage-innovation-and-production-and-enable-europe-to-make-up-lost-ground/2023-10-11T08:00:27+02:00https://distefar.com/en/farmaindustria-lanza-una-propuesta-para-acelerar-la-llegada-de-los-medicamentos-innovadores-a-pacientes-en-casos-donde-el-beneficio-es-mas-relevante-2/2023-10-17T10:06:07+02:00https://distefar.com/en/precision-medicine-opens-new-hopes-in-breast-cancer-14-targeted-therapies-authorized-since-2018/2023-10-24T11:40:48+02:00https://distefar.com/en/new-drugs-reduce-cancer-deaths-in-spain-by-almost-30/2023-10-30T13:51:40+01:00https://distefar.com/en/medicines-for-rare-diseases-already-account-for-39-of-those-authorised-in-europe-but-take-more-than-two-years-to-reach-spain/2023-11-02T08:12:30+01:00https://distefar.com/en/farmaindustrias-protection-of-personal-data-in-research-is-already-a-benchmark-in-europe-and-is-a-further-incentive-to-attract-clinical-trials-to-spain/2023-11-13T14:37:02+01:00https://distefar.com/en/the-european-health-data-space-is-a-unique-opportunity-that-will-improve-research-and-innovation-for-the-whole-of-society/2023-11-21T11:46:04+01:00https://distefar.com/en/boosting-clinical-research-in-primary-care-an-opportunity-for-patients-professionals-and-the-health-system/2023-11-27T12:15:55+01:00https://distefar.com/en/clinical-trials-are-a-hope-for-patients-with-rare-diseases-and-already-account-for-25-of-all-research-done-in-spain/2023-12-01T09:40:16+01:00https://distefar.com/en/the-european-health-data-space-is-an-opportunity-to-gain-greater-efficiency-in-cancer-drug-research/2023-12-11T13:52:24+01:00https://distefar.com/en/rd-investment-in-the-pharmaceutical-industry-reaches-1-4-billion-euros-in-spain-and-grows-by-10-in-just-one-year/2023-12-19T09:25:51+01:00https://distefar.com/en/paediatricians-join-project-to-boost-clinical-research-in-primary-care/2023-12-21T10:31:12+01:00https://distefar.com/en/the-pharmaceutical-industry-a-strategic-sector-for-spain-and-europe/2024-01-08T14:39:29+01:00https://distefar.com/en/the-distefar-team-is-environmentally-conscious-and-switches-from-buying-single-use-plastic-bottles-to-glass-bottles/2024-01-11T13:59:51+01:00https://distefar.com/en/fda-approves-55-new-drugs-in-2023-one-of-the-highest-numbers-in-a-decade/2024-01-15T13:33:10+01:00https://distefar.com/en/frank-r-lichtenberg-professor-at-columbia-university-life-expectancy-of-cancer-patients-in-spain-has-increased-by-almost-three-years-in-the-last-decade-thanks-to-the-use-of-innovative-drugs/2024-01-30T13:09:33+01:00https://distefar.com/en/a-common-catalogue-of-biomarkers-in-the-national-health-system-is-a-great-step-forward-for-patients-because-it-improves-access-to-personalised-medicine/2024-02-01T09:45:48+01:00https://distefar.com/en/the-innovative-medicines-platform-sets-its-roadmap-for-2024-with-the-aim-of-turning-spain-into-a-major-biomedical-innovation-hub/2024-02-02T08:25:52+01:00https://distefar.com/en/europe-calls-latest-cancer-drugs-significant-progress-for-health/2024-02-06T10:23:15+01:00https://distefar.com/en/spain-is-the-country-with-the-highest-participation-in-clinical-trials-of-new-drugs-in-europe/2024-02-08T10:39:51+01:00https://distefar.com/en/the-andalusian-regional-government-and-farmaindustria-will-promote-rdi-in-health-with-a-special-focus-on-the-promotion-of-clinical-trials/2024-02-13T10:51:56+01:00https://distefar.com/en/22-of-clinical-trials-underway-in-spain-seek-new-treatments-for-rare-diseases/2024-03-05T10:03:52+01:00https://distefar.com/en/spain-takes-on-average-two-years-to-approve-a-drug-for-a-minority-disease/2024-03-07T11:54:36+01:00https://distefar.com/en/the-health-sector-essential-for-the-well-being-of-the-population-and-an-economic-engine-for-society/2024-03-19T14:51:31+01:00https://distefar.com/en/hpv-the-success-of-a-vaccine-to-prevent-cancer-and-why-it-is-important-to-spread-it-worldwide/2024-04-02T13:46:17+02:00https://distefar.com/en/technology-and-innovation-platforms-key-elements-of-spains-rdi-system/2024-04-03T14:33:36+02:00https://distefar.com/en/innovation-as-a-patients-right/2024-04-22T13:14:40+02:00https://distefar.com/en/spain-a-clinical-trials-powerhouse/2024-04-24T10:13:29+02:00https://distefar.com/en/precision-medicine-and-new-medicines-require-the-modernisation-of-evaluation-and-funding-processes-including-the-social-perspective-and-the-economic-contribution-to-the-country/2024-04-30T11:34:36+02:00https://distefar.com/en/farmaindustria-launches-jovenes-en-farma-a-web-space-to-raise-awareness-of-job-opportunities-in-the-sector-and-connect-junior-talent-with-companies/2024-05-13T13:28:28+02:00https://distefar.com/en/the-european-health-technology-assessment-regulation-an-opportunity-to-speed-up-access-to-new-medicines-for-patients-in-spain/2024-05-15T08:35:13+02:00https://distefar.com/en/these-are-the-10-reasons-why-spain-is-a-world-leader-in-clinical-trials/2024-05-23T15:05:55+02:00https://distefar.com/en/latin-american-countries-interested-in-the-successful-model-of-clinical-trials-in-spain-promoted-by-farmaindustria/2024-06-17T15:04:39+02:00https://distefar.com/en/farmaindustria-promotes-its-project-to-increase-clinical-research-in-primary-care-in-the-autonomous-communities-of-spain/2024-06-25T10:33:30+02:00https://distefar.com/en/semfyc-and-farmaindustria-collaborate-to-promote-clinical-trials-in-primary-care/2024-07-09T08:20:38+02:00https://distefar.com/en/medicines-as-a-strategic-asset/2024-07-10T13:08:39+02:00https://distefar.com/en/the-innovative-pharmaceutical-industry-maintains-its-role-as-a-leading-sector-in-rd-investment-and-exports-in-europe-but-loses-positions-worldwide-surpassed-by-the-usa-and-now-also-by-china/2024-07-23T08:23:40+02:00https://distefar.com/en/el-valor-del-medicamento-de-marca-2/2024-07-30T08:36:50+02:00https://distefar.com/en/innovative-leadership-productive-capacity-and-the-ability-to-drive-the-countrys-economic-and-social-growth-make-the-pharmaceutical-industry-an-essential-strategic-sector/2024-09-17T12:49:05+02:00https://distefar.com/en/the-draghi-report-recognises-the-pharmaceutical-industry-as-a-strategic-pillar-in-europe-that-should-be-strengthened/2024-09-19T09:52:34+02:00https://distefar.com/en/pharmaceutical-companies-at-the-forefront-of-adopting-ai-across-the-entire-drug-lifecycle/2024-09-24T09:54:46+02:00https://distefar.com/en/patient-safety-a-pharmaceutical-industry-commitment-throughout-the-life-of-a-medicine/2024-09-26T11:30:14+02:00https://distefar.com/en/europe-streamlines-access-to-clinical-trial-information/2024-09-27T13:12:20+02:00https://distefar.com/en/el-sector-sanitario-a-la-espera-de-los-cambios-normativos-que-vienen-es-un-momento-critico-2/2024-10-08T10:18:22+02:00https://distefar.com/en/spain-advances-in-paediatric-clinical-research-through-international-projects-based-on-public-private-partnerships/2024-10-22T14:01:14+02:00https://distefar.com/en/fina-llados-new-president-of-farmaindustria-i-will-work-to-generate-confidence-and-make-the-industry-strategic-in-the-economic-and-social-development-of-spain/2024-10-24T09:49:26+02:00https://distefar.com/en/new-report-on-clinical-trials-places-spain-as-a-leader-and-success-story-in-europe/2024-10-29T10:47:04+01:00https://distefar.com/en/puertas-abiertas-a-la-investigacion-2/2024-10-31T09:46:06+01:00https://distefar.com/en/farmaindustria-connects-eight-research-projects-from-spanish-universities-and-small-companies-with-15-representatives-from-pharmaceutical-companies/2024-11-05T13:17:45+01:00https://distefar.com/en/good-implementation-of-pharmacogenomic-markers-will-optimise-the-use-of-medicines-and-improve-health-outcomes/2024-11-12T10:00:58+01:00https://distefar.com/en/advances-the-strategy-to-promote-clinical-trials-in-primary-care-centres-which-will-bring-new-treatment-opportunities-to-patients-in-spain/2024-11-15T08:38:43+01:00https://distefar.com/en/public-investment-in-medicines-remains-stable-in-terms-of-gdp-which-reinforces-the-idea-of-long-term-financial-sustainability/2024-11-18T16:59:33+01:00https://distefar.com/en/el-impacto-de-la-industria-farmaceutica-innovadora-en-europa-46-200-millones-de-euros-de-inversion-en-id-y-generacion-de-mas-23-millones-de-empleos-2/2024-11-20T12:18:57+01:00https://distefar.com/en/farmaindustria-destaca-el-cambio-de-paradigma-que-supone-la-ia-en-la-investigacion-biomedica-2/2024-12-03T10:02:30+01:00https://distefar.com/en/tres-claves-para-entender-el-mercado-farmaceutico-sostenibilidad-competencia-y-precios-2/2024-12-05T09:53:14+01:00https://distefar.com/en/the-spanish-medicines-agency-authorises-for-the-first-time-in-spain-a-phase-i-clinical-trial-under-the-accelerated-assessment-procedure/2024-12-17T13:17:33+01:00https://distefar.com/en/los-ensayos-clinicos-en-primaria-mejoran-la-salud-de-los-pacientes-2/2024-12-19T10:26:11+01:00https://distefar.com/en/las-10-areas-que-seran-clave-para-el-avance-de-la-innovacion-biomedica-en-los-proximos-anos-2/2024-12-20T10:50:57+01:00https://distefar.com/en/la-industria-farmaceutica-mundial-invierte-casi-el-30-de-sus-ingresos-en-id-lo-que-supone-cerca-de-270-000-millones-de-euros-2/2025-01-15T09:18:39+01:00https://distefar.com/en/espana-lider-de-europa-en-investigacion-clinica-de-medicamentos-2/2025-01-16T09:50:38+01:00https://distefar.com/en/mas-de-ocho-de-cada-10-ensayos-clinicos-que-se-realizan-en-espana-los-promueve-la-industria-farmaceutica-2/2025-01-20T13:56:48+01:00https://distefar.com/en/farmaindustria-fija-dos-objetivos-en-investigacion-biomedica-para-2025-afianzar-el-liderazgo-de-espana-en-ensayos-clinicos-e-impulsar-la-investigacion-traslacional-2/2025-01-22T09:20:07+01:00https://distefar.com/en/pharmaceutical-rd-pays-off-46-new-innovative-medicines-to-arrive-in-2024/2025-01-28T09:24:52+01:00https://distefar.com/en/biogipuzkoa-and-farmaindustria-promote-a-programme-to-awaken-vocations-train-in-health-research-and-attract-talent-among-young-people/2025-01-30T09:04:13+01:00https://distefar.com/en/biomarcadores-y-tratamientos-personalizados-diagnostico-y-prevencion-combinacion-perfecta-frente-al-cancer-2/2025-02-11T09:46:55+01:00https://distefar.com/en/la-industria-farmaceutica-genera-mas-de-27-000-millones-de-euros-de-valor-anadido-en-espana-casi-el-2-del-pib-del-pais-2/2025-02-13T08:45:55+01:00https://distefar.com/en/la-industria-farmaceutica-apuesta-por-espana-con-inversiones-de-9-000-millones-de-euros-y-pide-al-presidente-del-gobierno-seguir-apoyando-reformas-legislativas-que-favorezcan-la-innovacion-la-autono-2/2025-02-20T10:58:30+01:00https://distefar.com/en/distefar-ha-estado-presente-en-el-clinical-trial-supply-and-temperature-controlled-logistics-in-biopharmaceuticals-europeo-2025-los-dias-25-y-26-de-febrero-2/2025-03-04T11:45:09+01:00https://distefar.com/en/espana-tiene-en-marcha-mas-de-1-050-ensayos-clinicos-para-enfermedades-raras-y-nueve-de-cada-diez-estan-promovidos-por-la-industria-farmaceutica/2025-03-06T08:37:55+01:00https://distefar.com/en/responsables-de-sanidad-autonomicos-y-farmaindustria-se-reunen-para-analizar-la-nueva-regulacion-farmaceutica-el-buen-uso-de-los-medicamentos-y-los-avances-en-salud-digital-2/2025-03-18T09:55:28+01:00https://distefar.com/en/la-industria-farmaceutica-mundial-tenia-en-2024-12-700-medicamentos-en-desarrollo-2/2025-04-08T11:52:16+02:00https://distefar.com/en/posicionamiento-conjunto-ante-el-anteproyecto-de-ley-de-los-medicamentos-y-productos-sanitarios-2/2025-04-22T13:13:15+02:00https://distefar.com/en/espana-caso-de-exito-en-europa-en-ensayos-clinicos-de-nuevos-medicamentos-2/2025-05-08T10:53:34+02:00https://distefar.com/en/fina-llados-tenemos-ante-nosotros-una-oportunidad-unica-en-estos-desarrollos-legislativos-para-transformar-nuestra-sanidad-y-prepararla-para-los-proximos-20-anos-2/2025-05-12T10:02:36+02:00https://distefar.com/en/farmaindustria-presenta-mejoras-al-anteproyecto-de-ley-de-medicamentos-para-preparar-la-sanidad-para-la-innovacion-de-los-proximos-20-anos-2/2025-05-13T11:50:44+02:00https://distefar.com/en/los-hospitales-espanoles-a-la-cabeza-de-la-investigacion-clinica-en-europa-2/2025-05-21T10:13:53+02:00https://distefar.com/en/revision-de-la-legislacion-farmaceutica-la-oportunidad-clave-para-relanzar-la-competitividad-de-eu-2/2025-05-22T10:17:24+02:00https://distefar.com/en/un-marco-regulatorio-adecuado-y-mas-impulso-a-la-innovacion-claves-para-aumentar-la-competitividad-en-investigacion-biomedica-2/2025-05-23T09:09:10+02:00https://distefar.com/en/la-inversion-en-id-de-las-companias-farmaceuticas-innovadoras-supera-los-1-500-millones-de-euros-en-2024-2/2025-05-27T10:11:12+02:00https://distefar.com/en/el-isciii-y-farmaindustria-firman-un-acuerdo-para-fomentar-la-investigacion-biomedica-y-sanitaria-en-espana-2/2025-06-25T10:47:54+02:00https://distefar.com/en/un-estudio-identifica-proteinas-implicadas-en-la-eficacia-de-la-inmunoterapia-contra-el-cancer-de-sangre-2/2025-07-28T12:55:34+02:00https://distefar.com/en/la-receta-australiana-para-reforzar-la-capacidad-en-investigacion-medica-y-liderar-el-camino-de-la-proxima-decada-2/2025-09-15T09:56:27+02:00https://distefar.com/en/farmaindustria-celebra-el-anuncio-de-la-aemps-de-ampliar-la-evaluacion-acelerada-de-ensayos-clinicos-en-fases-tempranas-porque-refuerza-el-ecosistema-espanol-de-investigacion-biomedica-2/2025-09-16T12:29:14+02:00https://distefar.com/en/la-comunidad-de-madrid-aspira-a-ser-el-silicon-valley-del-sector-farmaceutico-2/2025-09-17T08:49:35+02:00https://distefar.com/en/terapias-avanzadas-en-linfoma-seis-anos-de-car-t-que-han-cambiado-la-vida-de-los-pacientes/2025-09-24T10:46:00+02:00https://distefar.com/en/espana-lider-europeo-en-ensayos-clinicos-contra-el-cancer-gracias-a-la-agilidad-y-la-atomizacion-de-los-grupos-de-investigacion-2/2025-09-30T10:47:54+02:00https://distefar.com/en/innovacion-y-datos-al-servicio-de-la-investigacion-clinica-2/2025-10-02T09:53:47+02:00https://distefar.com/en/espana-afianza-su-liderazgo-en-ensayos-clinicos-con-una-nueva-guia-que-impulsa-la-innovacion-la-digitalizacion-y-la-sostenibilidad-desde-la-farmacia-hospitalaria-2/2025-10-07T13:01:31+02:00https://distefar.com/en/espana-tiene-una-gran-oportunidad-en-el-sector-biofarmaceutico-pero-debe-revisar-sus-politicas-para-mantener-e-incrementar-su-potencial-y-atraer-inversiones-en-id-y-en-activos-industriales-2/2025-10-14T10:03:24+02:00https://distefar.com/en/el-contexto-geopolitico-situa-a-espana-ante-la-gran-oportunidad-de-atraer-inversiones-al-sector-biofarmaceutico-2/2025-10-21T14:50:58+02:00https://distefar.com/en/foro-mundial-de-ensayos-clinicos-solo-prosperaran-los-que-sean-eticos-de-alta-calidad-e-inclusivos-2/2025-10-27T13:26:20+01:00https://distefar.com/en/los-aranceles-de-eeuu-amenazan-la-industria-farmaceutica-europea-su-valor-podria-caer-hasta-un-5-2/2025-10-29T10:46:35+01:00https://distefar.com/en/un-estudio-de-celulas-madre-abre-la-puerta-a-regenerar-el-cerebro-tras-un-ictus-2/2025-10-30T09:20:18+01:00https://distefar.com/en/la-revolucion-del-medicamento-inteligente-reconfigura-el-mercado-farmaceutico-global-2/2025-11-05T09:30:53+01:00https://distefar.com/en/distefar-muy-concienciado-con-el-medioambiente-se-congratula-y-se-hace-eco-de-la-transformacion-ambiental-que-esta-experimentando-la-industria-farmaceutica-hacia-la-sostenibilidad-2/2025-11-10T08:39:55+01:00https://distefar.com/en/acercando-la-ciencia-a-las-escuelas-una-decada-formando-a-jovenes-en-investigacion-clinica-y-despertando-vocaciones-2/2025-11-12T11:44:48+01:00https://distefar.com/en/los-ensayos-clinicos-adaptativos-pieza-clave-para-transformar-el-desarrollo-de-vacunas-a-nivel-global-2/2025-11-19T10:58:26+01:00https://distefar.com/en/espana-da-un-paso-clave-con-el-nuevo-mapa-y-observatorio-autonomicos-de-investigacion-clinica-en-atencion-primaria-2/2025-12-02T14:06:57+01:00https://distefar.com/en/el-primer-fast-track-para-ensayos-clinicos-multinacionales-en-europa-arrancara-en-enero-de-2026-y-contribuira-a-reforzar-la-competitividad-europea-en-la-materia-2/2025-12-10T09:45:24+01:00https://distefar.com/en/los-ensayos-clinicos-se-acercan-al-pacientes-a-traves-de-la-atencion-primaria-2/2025-12-11T08:56:43+01:00https://distefar.com/en/europa-tiene-el-potencial-para-ser-lider-en-la-investigacion-desarrollo-y-produccion-de-nuevos-medicamentos-2/2025-12-16T10:35:03+01:00https://distefar.com/en/la-reforma-de-la-legislacion-farmaceutica-de-la-ue-insuficiente-para-mantener-la-competitividad-frente-a-eeuu-y-asia-2/2025-12-16T13:38:51+01:00https://distefar.com/en/patient-engagement-y-eficiencia-en-ensayos-clinicos-la-oportunidad-que-la-industria-no-puede-ignorar-2/2026-01-08T11:27:50+01:00https://distefar.com/en/el-contexto-geopolitico-situa-a-espana-ante-la-gran-oportunidad-de-atraer-inversiones-al-sector-biofarmaceutico-3-2/2026-01-13T11:00:06+01:00https://distefar.com/en/sostenibilidad-si-eficiencia-y-competitividad-tambien-2/2026-01-13T11:10:47+01:00https://distefar.com/en/espana-lidera-la-investigacion-clinica-en-la-ue-962-ensayos-autorizados-y-agilidad-administrativa-record-2/2026-01-14T10:18:22+01:00https://distefar.com/en/espana-vuelve-a-liderar-los-ensayos-clinicos-en-europa-pero-afronta-el-reto-de-competir-en-la-carrera-biomedica-global-2/2026-01-20T10:18:29+01:00https://distefar.com/en/la-industria-farmaceutica-valora-el-decalogo-de-buenas-practicas-en-el-uso-de-la-ia-en-el-desarrollo-de-medicamentos-elaborado-por-la-ema-y-la-fda-2/2026-01-27T11:07:48+01:00https://distefar.com/en/gepac-y-farmaindustria-firman-un-convenio-para-impulsar-la-investigacion-el-acceso-a-la-innovacion-y-la-medicion-de-resultados-en-salud-en-oncologia-2/2026-01-27T11:16:04+01:00https://distefar.com/en/la-inteligencia-artificial-acelera-el-desarrollo-de-farmacos-pero-aun-no-descubre-la-molecula-milagro-2/2026-01-29T08:42:34+01:00https://distefar.com/en/la-guia-de-excelencia-para-la-realizacion-de-ensayos-clinicos-en-la-farmacia-hospitalaria-reconocida-con-el-premio-diagnostico-2/2026-02-03T10:32:33+01:00https://distefar.com/en/del-potencial-a-los-resultados-asi-miden-las-companias-farmaceuticas-el-impacto-de-la-ia-en-sus-previsiones-2/2026-02-05T09:54:37+01:00https://distefar.com/en/la-inteligencia-artificial-permite-una-estratificacion-mas-precisa-del-riesgo-de-cancer-de-mama-2/2026-02-09T11:13:35+01:00https://distefar.com/en/35-000-nuevos-pacientes-tratados-18-000-empleos-creados-y-tres-millones-de-dias-de-baja-evitados-los-beneficios-de-cumplir-los-objetivos-de-la-ue-para-atraer-ensayos-clinicos-2/2026-03-04T13:35:08+01:00https://distefar.com/en/la-industria-farmaceutica-casi-triplica-su-inversion-en-espana-2/2026-03-05T09:08:55+01:00https://distefar.com/en/ayuso-anuncia-un-incremento-del-34-en-la-inversion-en-investigacion-cientifica-y-alcanza-los-752-millones-de-euros-2/2026-03-06T12:35:47+01:00https://distefar.com/en/la-cooperacion-internacional-en-la-industria-farmaceutica-clave-para-la-innovacion-y-el-acceso-global-2/2026-03-11T10:52:28+01:00https://distefar.com/en/the-fda-warns-that-30-of-clinical-trials-in-the-us-do-not-report-their-results/2026-04-17T10:07:37+02:00https://distefar.com/en/clinical-trials-for-rare-diseases-have-increased-by-4-in-spain-with-catalonia-madrid-and-andalusia-leading-the-way/2026-05-20T11:51:42+02:00https://distefar.com/en/clinical-trials-as-catalysts-for-change-in-clinical-practice-for-healthcare-professionals/2026-03-17T10:29:42+01:00https://distefar.com/en/madrid-is-launching-a-groundbreaking-clinical-trial-that-paves-the-way-for-pioneering-treatments-for-als/2026-03-20T11:46:45+01:00https://distefar.com/en/the-pharmaceutical-industry-and-its-environmental-footprint-the-urgent-challenge-of-transforming-its-packaging/2026-03-23T09:42:50+01:00https://distefar.com/en/200-new-medicines-and-nearly-e18-billion-for-the-european-economy-the-potential-of-a-more-competitive-biopharmaceutical-sector-over-the-next-decade/2026-03-24T09:57:26+01:00https://distefar.com/en/spain-is-preparing-to-move-from-clinical-trials-to-the-successful-use-of-health-data/2026-03-27T09:55:08+01:00https://distefar.com/en/nanotechnology-is-driving-a-new-generation-of-more-effective-and-personalised-medicines/2026-04-08T11:20:32+02:00https://distefar.com/en/fortrea-is-driving-the-digitalisation-of-clinical-trials-with-an-ai-powered-platform/2026-04-09T09:35:44+02:00https://distefar.com/en/spain-is-stepping-up-the-pace-in-the-long-term-race-for-clinical-trials/2026-04-14T13:03:42+02:00https://distefar.com/en/how-the-geopolitical-situation-is-affecting-medicines-in-spain/2026-04-16T09:16:54+02:00https://distefar.com/en/the-high-cost-of-pharmaceutical-failure-when-a-failed-trial-affects-the-entire-business-strategy/2026-04-20T09:13:30+02:00https://distefar.com/en/experimental-drugs-between-innovation-and-clinical-uncertainty/2026-04-27T11:53:23+02:00https://distefar.com/en/the-us-and-china-are-stepping-up-the-race-for-global-pharmaceutical-innovation/2026-04-28T10:14:46+02:00https://distefar.com/en/fina-llados-europe-must-take-action-to-avoid-falling-behind-in-biomedical-research-and-access-to-the-most-innovative-medicines/2026-04-29T10:26:14+02:00https://distefar.com/en/the-fda-is-launching-a-pilot-programme-to-monitor-clinical-trials-in-real-time/2026-04-30T10:23:06+02:00https://distefar.com/en/fda-inspections-uncover-recurring-shortcomings-in-clinical-trials-worldwide/2026-05-04T11:30:17+02:00https://distefar.com/en/spain-attracts-hundreds-of-clinical-trials-offering-a-last-hope-to-thousands-of-patients-without-research-we-are-lost/2026-05-05T10:10:45+02:00https://distefar.com/en/ten-key-points-for-maintaining-competitiveness-in-europe/2026-05-07T08:30:33+02:00https://distefar.com/en/ensayos-is-launched-a-platform-designed-to-highlight-the-importance-of-clinical-trials-and-the-people-who-make-them-possible/2026-05-26T11:13:41+02:00https://distefar.com/en/the-time-taken-to-gain-access-to-new-medicines-has-fallen-to-537-days-although-this-is-still-far-from-the-180-day-limit-set-by-the-european-directive/2026-05-27T12:51:20+02:00https://distefar.com/en/spain-can-take-the-decisive-leap-forward-in-biomedical-research-from-a-scientific-powerhouse-to-a-global-leader/2026-06-02T10:32:18+02:00https://distefar.com/en/biomedical-research-in-spain-between-leadership-bureaucratic-red-tape-and-the-challenge-of-data-management/2026-06-09T13:49:08+02:00https://distefar.com/en/pharmaceutical-innovation-has-seen-its-investment-in-europe-increase-fivefold-with-a-profit-of-66000-million/2026-06-24T10:39:01+02:00https://distefar.com/en/us-speeds-up-clinical-trials-the-biotechnology-industry-calls-on-the-fda-to-standardise-the-drug-approval-process/2026-06-26T08:29:05+02:00https://distefar.com/en/the-pharmaceutical-industry-is-warning-europe-that-it-will-lose-investment-if-it-does-not-pay-more-for-innovative-medicines/2026-06-26T08:33:59+02:00https://distefar.com/en/icon-joins-forces-with-microsoft-to-revolutionise-clinical-trials-using-artificial-intelligence/2026-06-29T12:47:50+02:00https://distefar.com/en/unresolved-issues-in-medical-science-spain-leads-the-way-in-clinical-trials-but-only-8-per-cent-reach-primary-care/2026-06-30T11:33:22+02:00